The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus
- 18 May 2020
- Vol. 61 (6), E66-E70
- https://doi.org/10.1111/epi.16534
Abstract
The Established Status Epilepticus Treatment Trial was a blinded, comparative‐effectiveness study of fosphenytoin, levetiracetam, and valproic acid in benzodiazepine‐refractory status epilepticus. The primary outcome was clinical seizure cessation and increased responsiveness without additional anticonvulsant medications. Weight‐based dosing was capped at 75 kg. Hence, patients weighing >75 kg received a lower mg/kg dose. Logistic regression models were developed in 235 adults to determine the association of weight (≤ or >75 kg, ≤ or >90 kg), sex, treatment, and weight‐normalized dose with the primary outcome and solely seizure cessation. The primary outcome was achieved in 45.1% and 42.5% of those ≤75 kg and >75 kg, respectively. Using univariate analyses, the likelihood of success for those >75 kg (odds ratio [OR] = 0.9, 95% confidence interval [CI] = 0.54‐1.51) or >90 kg (OR = 0.85, 95% CI = 0.42‐1.66) was not statistically different compared with those ≤75 kg or ≤90 kg, respectively. Similarly, other predictors were not significantly associated with primary outcome or clinical seizure cessation. Our findings suggest that doses, capped at 75 kg, likely resulted in concentrations greater than those needed for outcome. Studies that include drug concentrations and heavier individuals are needed to confirm these findings.Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS099653, U01NS056975, U01NS059041, U01NS088023, U01NS088034)
- College of Pharmacy, University of Minnesota
This publication has 9 references indexed in Scilit:
- Randomized Trial of Three Anticonvulsant Medications for Status EpilepticusThe New England Journal of Medicine, 2019
- Lessons from the Established Status Epilepticus Treatment TrialEpilepsy & Behavior, 2019
- Influence of Sex, Age, and Weight on Levetiracetam PharmacokineticsTherapeutic Drug Monitoring, 2018
- IV fosphenytoin in obese patientsNeurology Clinical Practice, 2017
- Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- Safety and pharmacokinetics of intravenous levetiracetam infusion as add‐on in status epilepticusEpilepsia, 2009
- Population pharmacokinetics of intravenous valproic acid in Korean patientsJournal of Clinical Pharmacy & Therapeutics, 2002
- Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case studyJournal of Clinical Pharmacy & Therapeutics, 1996
- Phenytoin Disposition in ObesityArchives of Neurology, 1985